What Brainfarma does

Brainfarma Indústria Química e Farmacêutica S.A. is a Brazilian pharmaceutical manufacturer operating as the production arm of Hypera Pharma (B3: HYPE3), one of Brazil's largest pharmaceutical groups. The company operates a large-scale industrial complex in Anápolis (Goias) with over 120,000 m² of built area, supported by approximately 4,600 manufacturing employees, and a research and development center branded "Hynova" in Barueri (São Paulo) with roughly 450 staff and 150 simultaneous development projects across six laboratories. A third manufacturing unit in Itapecerica is also referenced, bringing total headcount above 5,000.

The company manufactures more than 830 distinct products across more than 20 pharmaceutical forms, including solids, liquids, semisolids, effervescent formulations, injectables, and aerosols, positioning it among the largest pharmaceutical manufacturers in Latin America by product breadth and production capacity. Its R&D function (Hynova) handles formulation, analytical development, and process engineering for both generic and branded medicines destined for Hypera's commercial portfolio and, presumably, third-party demand within Brazil's regulated pharmaceutical market.

The business model is industrial-B2B: Brainfarma produces pharmaceutical dosage forms that flow through Hypera Pharma's commercialization and distribution infrastructure (which spans retail pharmacy chains, independent drugstores, and government channels via CMED-regulated pricing). Revenue accrues primarily through intragroup transfers within the Hypera consolidation perimeter; the company does not appear to market finished products directly to end consumers under its own brand at retail, but supplies Hypera's branded and generic lines. Governance signals include UN Global Compact signatory status, Top Employers 2025 certification, and the publication of a 2022 Code of Ethics guide. No standalone revenue figure, pricing schedule, or external customer roster is disclosed in the source material.

Name

Brainfarma

Legal name

Brainfarma Indústria Química e Farmacêutica S.A.

Website

https://brainfarma.ind.br

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Brainfarma is the manufacturing subsidiary of Hypera Pharma, operating large-scale pharmaceutical production in Anápolis and R&D (Hynova) in Barueri, producing 830+ products across 20+ dosage forms for Brazil's healthcare market.

Ownership category

akta.pro rank

Headquarters

HQ city

Anápolis

HQ country

Brazil

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Brainfarma generates revenue through the manufacturing and sale of pharmaceutical products, dermocosmetics, nutritional products, and vitamin supplements to the Brazilian market. The company operates as one of the largest pharmaceutical manufacturers in Brazil.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Brainfarma is a Brazilian pharmaceutical manufacturer that develops and produces medications, dermocosmetics, nutritional products, and vitamin supplements at its Anápolis manufacturing facility (one of the largest in Latin America, with capacity for 830+ distinct items across more than 20 pharmaceutical forms) and at the Hynova research and development center in Barueri (six laboratories, approximately 150 simultaneous development projects, around 450 R&D professionals). The company operates as the manufacturing and R&D arm of Hypera Pharma, Brazil's largest pharmaceutical group, serving the Brazilian healthcare market through pharmaceutical distribution channels.

Product overview

Brainfarma is a pharmaceutical manufacturing company operating as part of Hypera Pharma group. The company operates two main facilities: a large manufacturing plant in Anápolis, Goiás (one of the largest in Latin America with 120,000 square meters) and the Hynova Research and Development Center in Barueri, São Paulo. The company manufactures pharmaceutical products in multiple forms (solids, liquids, semisolids, effervescent, injectables, aerosols) and develops medications, dermocosmetics, nutritional products, and vitamin supplements through its R&D operations.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical medications (manufacturing) Manufactured medications produced at the Anápolis facility in multiple pharmaceutical forms (solids, liquids, semisolids, effervescents, injectables, aerosols) with capacity for more than 830 distinct items, distributed through pharmaceutical distribution channels to pharmacies, hospitals, and healthcare providers across Brazil.
• Dermocosmetics Dermocosmetic products developed at the Hynova R&D center and manufactured at scale, distributed through Brazilian pharmaceutical and healthcare retail channels.
• Nutritional products Nutritional product formulations developed at the Hynova R&D center and manufactured at scale for distribution through Brazilian pharmaceutical and healthcare channels.
• Vitamin supplements Vitamin supplement products developed at the Hynova R&D center and manufactured at scale at the Anápolis factory, distributed through Brazilian pharmaceutical retail and healthcare channels.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Hypera PharmacoreOthersBrainfarma is a subsidiary of Hypera Pharma (Hypera S/A). The parent company holds the CNPJ registration and provides corporate governance, terms of use, privacy policies, and ESG reporting for the Brainfarma website. Brainfarma operates as part of the Hypera Pharma group, with shared compliance and corporate standards.

Scale indicators6 records

Expansion highlights3 records

Direct peers

• EMS Pharma: One of Brazil's largest pharmaceutical manufacturers by volume, producing generics, branded drugs, and OTC products across multiple dosage forms. Directly comparable to Brainfarma as a domestic Brazilian pharma manufacturer competing on scale, portfolio breadth, and distribution reach.
• Eurofarma Laboratórios: Brazilian multinational pharmaceutical company with significant domestic manufacturing and R&D operations, producing branded generics, OTC, and hospital drugs. Comparable to Brainfarma in scale, multi-form manufacturing, and Brazilian market focus.
• Aché Laboratórios: Major Brazilian pharmaceutical manufacturer with branded generics, prescription, and consumer health products. Comparable in size, domestic focus, and vertically integrated R&D-and-manufacturing model similar to Brainfarma's.
• Cimed: Brazilian pharmaceutical group with large-scale manufacturing and a strong OTC and generics portfolio. Comparable to Brainfarma on production scale, product breadth, and aggressive pricing in the Brazilian market.
• Biolab Farmacêutica: Brazilian pharmaceutical manufacturer focused on prescription, generics, and dermocosmetics with its own R&D and manufacturing. Comparable to Brainfarma in product categories (including dermocosmetics) and Brazilian-market focus.
• Geolab Indústria Farmacêutica: Brazilian generics manufacturer with large multi-form production capacity supplying the public and private markets. Comparable to Brainfarma as a high-volume, multi-dosage-form Brazilian manufacturer.
• Cristália Produtos Químicos Farmacêuticos: Brazilian pharmaceutical and hospital products manufacturer with strong injectables and anesthetics portfolio. Comparable to Brainfarma on multi-form manufacturing, including higher-complexity injectables, and Brazilian-market focus.
• Prati-Donaduzzi: Brazilian generics manufacturer with large industrial footprint and broad product portfolio. Comparable to Brainfarma as a high-volume domestic manufacturer competing in generics and OTC.

Broad incumbents

• Hypera Pharma (parent group): Parent company of Brainfarma and Brazil's largest pharmaceutical company (HYPE3). Operates branded, OTC, generics, and consumer health brands nationwide. Comparable as the broader group that owns and commercializes Brainfarma's manufactured products.
• Medley (Sanofi Brasil): Generics-focused pharmaceutical brand in Brazil, owned by Sanofi. Comparable to Brainfarma in generics manufacturing and Brazilian retail distribution, though backed by a multinational parent with broader capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brainfarma